Rezultati pretraživanja
  1. 10. stu 2019.

    : 214 +Nivo seems better than IPI +NIVO. Adds CRs (34% vs. 11%) and PFS (>18 months vs. 11.5) w less Gr3-4 TAEs (17% vs 55%); But ORR in PDL-1 neg was 39% (Nivo+214) vs. 55% (Ipi + Nivo). Overall better.

  2. 10. stu 2019.

    stuff I saw at - the resurrection of IL2 (mhm) - a cautious Siglec15 reception - too many TLR7/8 posters - ditto cytokine x PD-L1 bispecific posters - a glimmer of hope for 4-1BB - THE MOST GORGEOUS IMAGING DATA

  3. My take on a few presentations (yes, I'm puzzled by ) via

    Prikaži ovu nit
  4. 10. stu 2019.

    Siglec-15 data at -No new responses in NSCLC -CR occurred in lowest 8mg dose - 0 response in 36 pts of other cancer types So is a CR for a 7.6mm lesion really worth >$1billion? Is a <10mm lesion even qualified as target lesion under RECIST?

  5. 13. stu 2019.

    Are you brave enough to sit through and get your body inked or just to watch people? Get your tickets now by going onto

  6. 9. stu 2019.

    Stopping IO early did not correlate with progression: those off ipi/nivo due to AE vs those who continued therapy with equal (maybe better) OS ➡️ Sparkathon resulting in randomized trial led by Thomas Marron and and collaboration with trial

  7. 13. stu 2019.

    Keep in mind that the best tattoo shop for the day wins a Motor Bike sponsored by Soweto Ink. So don’t miss out 💃🏽💃🏽

    Prikaži ovu nit
  8. 9. stu 2019.

    Encouraging monotx data for a Siglec15 targeting therapeutic in Phase I. Could be the first clinically important checkpoint inhibitor in the post-PDL1/PD1 world? Single agent activity, irAEs and anti-correlation with PDL1 expression are particularly interesting.

  9. 5. stu 2019.

    Timely update on trends in clinical development for PD-1/PD-L1 inhibitors into from Interesting data point on fast recruitment rate for cancer trials in China (for those wondering about why did deal on the dev side)

  10. 9. stu 2019.

    Dr. Thomas Marron presenting an update of our SITC Sparkathon team project.

  11. 8. stu 2019.

    finally made it here and excited to learn. Can we PLEASE have some trials for checkpoint resistant melanoma. I have a lot of patients. And make some prior immuno tox allowed!

  12. 9. stu 2019.
  13. 8. stu 2019.

    We will be at this weekend to present data showing how our CRISPRomics discovery engine can point the direction towards promising avenues of

  14. 10. stu 2019.

    Not so fast on this presentation is a major let down vs abstract. No new responders. CR was at lowest dose. Both responders not markered for s15 levels. PK not clean. Total of 49 patients across indications and 2 responses does not justify the stock at these levels.

  15. 9. stu 2019.

    Viyara Matson from Tom Gajewskis group is giving a fantastic talk on their work showing the importance of the microbiome on shaping the immune repertoire. Impressive single cell data showing key changes within the myeloid compartment

    Prikaži ovu nit
  16. 1. pro 2019.

    💋 it was incredible to meet Abby and her sister Charlotte at 2019 in 💋 – mjesto: NEC Atrium

    Prikaži ovu nit
  17. 8. stu 2019.

    Fascinating insights - for me at least. Many of the non mutated tumor antigens are in fact expressed in the context of inflammation = broad disease associated antigens. Universal vaccines ? Dr. Finn

  18. 8. stu 2019.

    Fantastic talk by Giuseppe Lamberti at on genomic correlates of PD-L1 expression in NSCLC!

  19. 5. stu 2019.

    +37% --> Biggest winner for abstracts release Single agent activity in NSCLC: BORR: 2/7 or 29%, DCR: 5/7 or 71% 1 CR (ongoing at 41 weeks) 1 PR (ongoing at 14 weeks) Siglec-15 mAb the next hot sexy thing in race?

  20. 8. stu 2019.

    Pleased to present our poster outlining positive new findings for our Lead Immunocytokine Program KY1043 at

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.